CN1387565A - 人胚胎干细胞的造血分化 - Google Patents
人胚胎干细胞的造血分化 Download PDFInfo
- Publication number
- CN1387565A CN1387565A CN00815326A CN00815326A CN1387565A CN 1387565 A CN1387565 A CN 1387565A CN 00815326 A CN00815326 A CN 00815326A CN 00815326 A CN00815326 A CN 00815326A CN 1387565 A CN1387565 A CN 1387565A
- Authority
- CN
- China
- Prior art keywords
- cell
- human
- hematopoietic cell
- hematopoietic
- culture
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 210000001671 embryonic stem cell Anatomy 0.000 title claims abstract description 21
- 230000003394 haemopoietic effect Effects 0.000 title claims description 7
- 230000004069 differentiation Effects 0.000 title description 15
- 210000003958 hematopoietic stem cell Anatomy 0.000 claims abstract description 53
- 238000000034 method Methods 0.000 claims abstract description 35
- 238000004113 cell culture Methods 0.000 claims abstract description 8
- 210000002536 stromal cell Anatomy 0.000 claims abstract description 5
- 210000004027 cell Anatomy 0.000 claims description 132
- 230000001332 colony forming effect Effects 0.000 claims description 16
- 210000001161 mammalian embryo Anatomy 0.000 claims description 10
- 230000011132 hemopoiesis Effects 0.000 claims description 9
- 229920000609 methyl cellulose Polymers 0.000 claims description 8
- 239000001923 methylcellulose Substances 0.000 claims description 8
- 210000004248 oligodendroglia Anatomy 0.000 claims description 8
- 102100031573 Hematopoietic progenitor cell antigen CD34 Human genes 0.000 claims description 5
- 101000777663 Homo sapiens Hematopoietic progenitor cell antigen CD34 Proteins 0.000 claims description 5
- 241000124008 Mammalia Species 0.000 claims description 3
- 210000001325 yolk sac Anatomy 0.000 claims description 3
- 108700018351 Major Histocompatibility Complex Proteins 0.000 claims description 2
- 238000002054 transplantation Methods 0.000 abstract description 8
- 210000000130 stem cell Anatomy 0.000 description 12
- 239000000243 solution Substances 0.000 description 11
- 239000000463 material Substances 0.000 description 9
- 210000003995 blood forming stem cell Anatomy 0.000 description 8
- 238000012360 testing method Methods 0.000 description 8
- 241000699666 Mus <mouse, genus> Species 0.000 description 7
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 7
- 239000002953 phosphate buffered saline Substances 0.000 description 7
- 210000001519 tissue Anatomy 0.000 description 7
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 6
- 210000004369 blood Anatomy 0.000 description 6
- 239000008280 blood Substances 0.000 description 6
- 239000012091 fetal bovine serum Substances 0.000 description 5
- 238000011081 inoculation Methods 0.000 description 5
- 239000002516 radical scavenger Substances 0.000 description 5
- 210000002966 serum Anatomy 0.000 description 5
- 238000011160 research Methods 0.000 description 4
- 244000309466 calf Species 0.000 description 3
- 230000001413 cellular effect Effects 0.000 description 3
- 238000005119 centrifugation Methods 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 238000004043 dyeing Methods 0.000 description 3
- 238000001943 fluorescence-activated cell sorting Methods 0.000 description 3
- 239000011521 glass Substances 0.000 description 3
- 238000003364 immunohistochemistry Methods 0.000 description 3
- 201000006417 multiple sclerosis Diseases 0.000 description 3
- 239000007787 solid Substances 0.000 description 3
- DGVVWUTYPXICAM-UHFFFAOYSA-N β‐Mercaptoethanol Chemical compound OCCS DGVVWUTYPXICAM-UHFFFAOYSA-N 0.000 description 3
- UZOVYGYOLBIAJR-UHFFFAOYSA-N 4-isocyanato-4'-methyldiphenylmethane Chemical compound C1=CC(C)=CC=C1CC1=CC=C(N=C=O)C=C1 UZOVYGYOLBIAJR-UHFFFAOYSA-N 0.000 description 2
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- 208000023275 Autoimmune disease Diseases 0.000 description 2
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 2
- 108010010803 Gelatin Proteins 0.000 description 2
- WZUVPPKBWHMQCE-UHFFFAOYSA-N Haematoxylin Chemical compound C12=CC(O)=C(O)C=C2CC2(O)C1C1=CC=C(O)C(O)=C1OC2 WZUVPPKBWHMQCE-UHFFFAOYSA-N 0.000 description 2
- 241000699670 Mus sp. Species 0.000 description 2
- 229930182555 Penicillin Natural products 0.000 description 2
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 2
- 241000288906 Primates Species 0.000 description 2
- PXIPVTKHYLBLMZ-UHFFFAOYSA-N Sodium azide Chemical compound [Na+].[N-]=[N+]=[N-] PXIPVTKHYLBLMZ-UHFFFAOYSA-N 0.000 description 2
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 238000013459 approach Methods 0.000 description 2
- 210000002960 bfu-e Anatomy 0.000 description 2
- 238000010322 bone marrow transplantation Methods 0.000 description 2
- 239000006285 cell suspension Substances 0.000 description 2
- 230000008878 coupling Effects 0.000 description 2
- 238000010168 coupling process Methods 0.000 description 2
- 238000005859 coupling reaction Methods 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 235000020776 essential amino acid Nutrition 0.000 description 2
- 239000003797 essential amino acid Substances 0.000 description 2
- 238000011156 evaluation Methods 0.000 description 2
- 238000001914 filtration Methods 0.000 description 2
- 238000000684 flow cytometry Methods 0.000 description 2
- 238000011010 flushing procedure Methods 0.000 description 2
- 238000007710 freezing Methods 0.000 description 2
- 230000008014 freezing Effects 0.000 description 2
- 229920000159 gelatin Polymers 0.000 description 2
- 239000008273 gelatin Substances 0.000 description 2
- 235000019322 gelatine Nutrition 0.000 description 2
- 235000011852 gelatine desserts Nutrition 0.000 description 2
- 239000001963 growth medium Substances 0.000 description 2
- 230000002607 hemopoietic effect Effects 0.000 description 2
- 230000036039 immunity Effects 0.000 description 2
- 230000001506 immunosuppresive effect Effects 0.000 description 2
- 230000006872 improvement Effects 0.000 description 2
- 230000002779 inactivation Effects 0.000 description 2
- 210000004153 islets of langerhan Anatomy 0.000 description 2
- 210000004698 lymphocyte Anatomy 0.000 description 2
- 239000003550 marker Substances 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- 210000000056 organ Anatomy 0.000 description 2
- 229940049954 penicillin Drugs 0.000 description 2
- 239000004033 plastic Substances 0.000 description 2
- 229920003023 plastic Polymers 0.000 description 2
- 239000002243 precursor Substances 0.000 description 2
- 238000004321 preservation Methods 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 230000035755 proliferation Effects 0.000 description 2
- 230000005855 radiation Effects 0.000 description 2
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 2
- 238000012546 transfer Methods 0.000 description 2
- YXHLJMWYDTXDHS-IRFLANFNSA-N 7-aminoactinomycin D Chemical compound C[C@H]1OC(=O)[C@H](C(C)C)N(C)C(=O)CN(C)C(=O)[C@@H]2CCCN2C(=O)[C@@H](C(C)C)NC(=O)[C@H]1NC(=O)C1=C(N)C(=O)C(C)=C2OC(C(C)=C(N)C=C3C(=O)N[C@@H]4C(=O)N[C@@H](C(N5CCC[C@H]5C(=O)N(C)CC(=O)N(C)[C@@H](C(C)C)C(=O)O[C@@H]4C)=O)C(C)C)=C3N=C21 YXHLJMWYDTXDHS-IRFLANFNSA-N 0.000 description 1
- 108700012813 7-aminoactinomycin D Proteins 0.000 description 1
- 208000032467 Aplastic anaemia Diseases 0.000 description 1
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 206010068051 Chimerism Diseases 0.000 description 1
- 102000029816 Collagenase Human genes 0.000 description 1
- 108060005980 Collagenase Proteins 0.000 description 1
- 102000003951 Erythropoietin Human genes 0.000 description 1
- 108090000394 Erythropoietin Proteins 0.000 description 1
- 102000004269 Granulocyte Colony-Stimulating Factor Human genes 0.000 description 1
- 108010017080 Granulocyte Colony-Stimulating Factor Proteins 0.000 description 1
- 102000004457 Granulocyte-Macrophage Colony-Stimulating Factor Human genes 0.000 description 1
- 108010017213 Granulocyte-Macrophage Colony-Stimulating Factor Proteins 0.000 description 1
- 206010062016 Immunosuppression Diseases 0.000 description 1
- 241000282560 Macaca mulatta Species 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- 210000001744 T-lymphocyte Anatomy 0.000 description 1
- 206010043276 Teratoma Diseases 0.000 description 1
- 102000004142 Trypsin Human genes 0.000 description 1
- 108090000631 Trypsin Proteins 0.000 description 1
- 238000002679 ablation Methods 0.000 description 1
- 230000000735 allogeneic effect Effects 0.000 description 1
- 238000011316 allogeneic transplantation Methods 0.000 description 1
- 239000000427 antigen Substances 0.000 description 1
- 230000030741 antigen processing and presentation Effects 0.000 description 1
- 108091007433 antigens Proteins 0.000 description 1
- 102000036639 antigens Human genes 0.000 description 1
- 230000001363 autoimmune Effects 0.000 description 1
- 230000006472 autoimmune response Effects 0.000 description 1
- 210000003719 b-lymphocyte Anatomy 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 210000002798 bone marrow cell Anatomy 0.000 description 1
- 229940098773 bovine serum albumin Drugs 0.000 description 1
- 229910052792 caesium Inorganic materials 0.000 description 1
- TVFDJXOCXUVLDH-UHFFFAOYSA-N caesium atom Chemical compound [Cs] TVFDJXOCXUVLDH-UHFFFAOYSA-N 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 210000004413 cardiac myocyte Anatomy 0.000 description 1
- 239000006143 cell culture medium Substances 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 238000001311 chemical methods and process Methods 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 238000002512 chemotherapy Methods 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 229960002424 collagenase Drugs 0.000 description 1
- 230000003750 conditioning effect Effects 0.000 description 1
- 230000009089 cytolysis Effects 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 210000002308 embryonic cell Anatomy 0.000 description 1
- 229940105423 erythropoietin Drugs 0.000 description 1
- 210000002950 fibroblast Anatomy 0.000 description 1
- MHMNJMPURVTYEJ-UHFFFAOYSA-N fluorescein-5-isothiocyanate Chemical compound O1C(=O)C2=CC(N=C=S)=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 MHMNJMPURVTYEJ-UHFFFAOYSA-N 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 210000003714 granulocyte Anatomy 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 208000019622 heart disease Diseases 0.000 description 1
- 230000007236 host immunity Effects 0.000 description 1
- 239000003018 immunosuppressive agent Substances 0.000 description 1
- 229940124589 immunosuppressive drug Drugs 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- 239000000543 intermediate Substances 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 210000005229 liver cell Anatomy 0.000 description 1
- 208000019423 liver disease Diseases 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 239000002609 medium Substances 0.000 description 1
- 210000001616 monocyte Anatomy 0.000 description 1
- 230000001400 myeloablative effect Effects 0.000 description 1
- 230000002107 myocardial effect Effects 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 238000010449 nuclear transplantation Methods 0.000 description 1
- 238000005457 optimization Methods 0.000 description 1
- 230000008520 organization Effects 0.000 description 1
- 210000000496 pancreas Anatomy 0.000 description 1
- OXCMYAYHXIHQOA-UHFFFAOYSA-N potassium;[2-butyl-5-chloro-3-[[4-[2-(1,2,4-triaza-3-azanidacyclopenta-1,4-dien-5-yl)phenyl]phenyl]methyl]imidazol-4-yl]methanol Chemical compound [K+].CCCCC1=NC(Cl)=C(CO)N1CC1=CC=C(C=2C(=CC=CC=2)C2=N[N-]N=N2)C=C1 OXCMYAYHXIHQOA-UHFFFAOYSA-N 0.000 description 1
- XJMOSONTPMZWPB-UHFFFAOYSA-M propidium iodide Chemical compound [I-].[I-].C12=CC(N)=CC=C2C2=CC=C(N)C=C2[N+](CCC[N+](C)(CC)CC)=C1C1=CC=CC=C1 XJMOSONTPMZWPB-UHFFFAOYSA-M 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 238000012797 qualification Methods 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 230000001846 repelling effect Effects 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 238000007790 scraping Methods 0.000 description 1
- 238000005204 segregation Methods 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 229960005322 streptomycin Drugs 0.000 description 1
- QTENRWWVYAAPBI-YCRXJPFRSA-N streptomycin sulfate Chemical compound OS(O)(=O)=O.OS(O)(=O)=O.OS(O)(=O)=O.CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](N=C(N)N)[C@H](O)[C@@H](N=C(N)N)[C@H](O)[C@H]1O.CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](N=C(N)N)[C@H](O)[C@@H](N=C(N)N)[C@H](O)[C@H]1O QTENRWWVYAAPBI-YCRXJPFRSA-N 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 239000008399 tap water Substances 0.000 description 1
- 235000020679 tap water Nutrition 0.000 description 1
- 238000010998 test method Methods 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 239000012588 trypsin Substances 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- 231100000054 whole-body exposure Toxicity 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0603—Embryonic cells ; Embryoid bodies
- C12N5/0606—Pluripotent embryonic cells, e.g. embryonic stem cells [ES]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
- C12N5/0647—Haematopoietic stem cells; Uncommitted or multipotent progenitors
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K2035/122—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells for inducing tolerance or supression of immune responses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K2035/124—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells the cells being hematopoietic, bone marrow derived or blood cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/10—Growth factors
- C12N2501/115—Basic fibroblast growth factor (bFGF, FGF-2)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2502/00—Coculture with; Conditioned medium produced by
- C12N2502/13—Coculture with; Conditioned medium produced by connective tissue cells; generic mesenchyme cells, e.g. so-called "embryonic fibroblasts"
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2502/00—Coculture with; Conditioned medium produced by
- C12N2502/13—Coculture with; Conditioned medium produced by connective tissue cells; generic mesenchyme cells, e.g. so-called "embryonic fibroblasts"
- C12N2502/1394—Bone marrow stromal cells; whole marrow
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2506/00—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells
- C12N2506/02—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells from embryonic cells
Landscapes
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Life Sciences & Earth Sciences (AREA)
- Biomedical Technology (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Organic Chemistry (AREA)
- Biotechnology (AREA)
- Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Genetics & Genomics (AREA)
- Hematology (AREA)
- General Health & Medical Sciences (AREA)
- Cell Biology (AREA)
- Biochemistry (AREA)
- General Engineering & Computer Science (AREA)
- Microbiology (AREA)
- Developmental Biology & Embryology (AREA)
- Immunology (AREA)
- Gynecology & Obstetrics (AREA)
- Reproductive Health (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Materials For Medical Uses (AREA)
Abstract
本文公开了用哺乳动物基质细胞从人胚胎干细胞获得人造血细胞的方法。用本方法衍生的造血细胞可用于制备适于移植、输血和其它目的的细胞培养物。
Description
与相关申请的相互参照:
没有适用的。
关于联邦政府赞助研究的声明
-- --
发明背景
本发明涉及用人胚胎干细胞来产生与血相关的细胞,和将这些与血相关的细胞用于各种目的。
最近我们实验室已描述了分离人胚胎干细胞稳定培养物的方法。参见美国专利No.5,843,780和J.Thomson等人,282 Science 1145-1147(1998)。这些出版物和以下所引用的所有出版物本文都全部纳入作为参考。
我们分别于1999年7月7日和1999年7月15日在美国典型培养物保藏中心(10801 University Boulevard,Manassas,Virginia 20110-2209,U.S.A)保藏了我们的两种人胚胎干细胞系。这两种保藏物的分类描述分别为人胚胎干细胞系H1和H9。在这些出版物中已指出这两种细胞系可与其它物质一起用来提供用于各种类型研究、移植和其它目的的特定的细胞系源。
在这些出版物所述的储存和培养条件下,这两种细胞系可以长期维持而不致分化成各种特定的细胞类型。当这两种细胞系被注射入免疫缺陷小鼠后,它们就可形成畸胎瘤,表明可分化成多样性组织类型。
当将胚胎干(ES)细胞用于产生所需的细胞时,往往侧重于优化向特定细胞类型的分化。对造血细胞而言,期望从而能得到可以分离并可用于形成多样性造血谱系的造血细胞。这些细胞包括(但不限制于)造血干细胞。
已从骨髓直接分离了若干造血干细胞群。参见C.Baum等人,89 PNAS USA2804-2808(1992)。但这依赖骨髓的供给来获得细胞。
人们已企图将鼠胚胎细胞群变成造血细胞。参见美国专利No.5,914,268;G.Keller,7 Current Opinion In Cell Biology,862-869(1995);和T.Nakano等人,265 Science 1098-1101(1994)。还可参见M.Weiss,11 Aplastic Anemia And StemCell Biology,1185-1195(1997);和S.Morrison等人,11 Annu.Rev.CellDev.Biol.,35-71(1995)。
但将这些方法施用于灵长类动物就很困难。例如,在F.Li等人,92 Blood368a(1998)中讨论了用基质细胞系和外源细胞因子进行猕猴胚胎干细胞系的分化。但最近该试验组报道它们的方法不足以形成集落。
用组织移植治疗各种疾病已日益普遍。但需要排队获得天然捐赠的器官、细胞或组织。即使得到了天然供体的材料,通常还存在排斥的问题。抑制接受者免疫应答的传统方法还存在缺陷。例如,免疫抑制药价格昂贵且往往有副作用。
在WO 98/07841中,公开了衍生出与所选供体MHC相容的胚胎干细胞的方法(如将供体的细胞核移植入去核的卵母细胞,然后从其衍生出干细胞)。此申请建议可用如此得到的细胞获得MHC相容的造血干细胞,用于需要骨髓移植的医学处理中。
然而,一些疾病如1型糖尿病或多发性硬化都涉及自身免疫应答。例如,将朗格罕氏体(pancreatic islets)(与患者是MHC相容的)替代受损的朗格罕氏体,并不能为减轻I型糖尿病提供足够长时间,因为宿主的免疫系统最终将攻击移植入的胰岛。
因此可以看出需要一种方法能让人胚胎干细胞培养物分化成所需的造血细胞集落。另外,需要开发造血细胞的改进用途。
发明概述
本发明的一方面提供了获得人造血细胞的方法。将人胚胎干细胞培养物与哺乳动物造血基质细胞相接触,从而产生人造血细胞。至少部分如此产生的人造血细胞是CD34+和/或能在甲基纤维素培养基上形成造血细胞集落形成单位。
如C.Baum等人,89 PNAS USA 2804-2808(1992)和S.Morrison等人,11Annu.Rev.Cell Dev.Biol.,35-71(1995)所述,CD34是造血干细胞的标准标记物。形成集落形成单位能力的特性是细胞具有形成更多分化的造血谱系所需的特性。
较佳的是从骨髓细胞或胚胎卵黄囊细胞衍生的基质细胞。鼠基质细胞可用于此目的。而灵长类和其它哺乳动物的基质细胞也都适合。
本发明的另一方面提供了从体外培养的人胚胎干细胞衍生出的人造血细胞,能在甲基纤维素培养物中形成造血细胞集落形成单位。在本专利中,术语“衍生的”指直接或间接(如,通过一种或多种中间体或一次或多次传代)获得的。
在本发明在另一方面提供了一种将人细胞物质移植入人受体宿主的方法。获得了在体外从胚胎干细胞培养物衍生的人造血细胞。然后获得了造血细胞以外的所选的人细胞物质,这种所选的非造血系材料具有与造血细胞相容的主要组织相容性复合物。然后将造血细胞和所选的非造血细胞物质一起转移到人类宿主。
例如,可以获得在体外从胚胎干细胞培养物(如用以下方法)衍生的人造血细胞。也可获得对造血细胞具有MHC相容性的人朗格罕氏体。然后将造血细胞和朗格罕氏体一起移植入人体(较佳的是,当受体本身的骨髓已失活后)。
可以从供体(其细胞用于产生胚胎干细胞培养物)直接获得朗格罕氏体。另外,单一的胚胎干细胞培养物可以按两种不同的途径分化。一种过程,可以用所述方法来产生造血干细胞。随后,当移植入合适的宿主后,这些细胞可发育成多样化的造血谱系。这些谱系包括能耐受从同一亲代胚胎干细胞衍生的其它细胞的淋巴细胞。在另一种过程中,将干细胞直接转化成朗格罕氏体。
在另一实施例中,可以向患多发性硬化的人提供少突神经胶质细胞。获得在体外从胚胎干细胞培养物衍生的人造血细胞(如用以下方法)。也可获得与骨髓细胞具有MHC相容性的人少突神经胶质细胞,并可将骨髓细胞和少突神经胶质细胞一起移植入人体。
其遗传物质用于产生胚胎干细胞的同一人可用作少突神经胶质细胞的供体。另外,相同的胚胎干细胞培养物可通过两种途径分化,从而提供两种可移植的物质。
通过这种方法可以降低疾病(和潜在的其它自身免疫疾病)的免疫和自身免疫排斥问题。由此看来,在移植前可用辐射或化学方法使接受者本来的骨髓完全或部分失活。然后至少部分用移植入的造血细胞替代。自身骨髓的清除/减少降低了身体产生自体免疫反应的能力。替换的骨髓和后继的可移植物质的MHC匹配确保了第二次物质不会被已移植的骨髓排斥。
另外,可进行造血细胞和其它组织的一起移植来促进对后继组织的接受(如用心肌与造血细胞一起来治疗心脏病;用肝细胞与造血细胞一起来治疗肝病)。通过产生造血系嵌合体,可以获得类似匹配MHC类型的组织对移植的改善的接受性。
本发明适用于获得广范围的有价值的造血细胞,如红细胞、粒细胞、巨噬细胞、淋巴细胞前体、单核细胞、B细胞、T细胞等。由此看来,在收获了分成单一类型细胞和接种于合适的培养基时,分化的ES细胞集落就可长成造血集落。这些集落表明集落形成细胞的发展可增殖成集落形成单位(包括集落形成单位-红细胞(CFU-E)、母细胞形成单位-红细胞(BFU-E)、集落形成单位-巨噬细胞(CFU-M)、集落形成单位-粒细胞/巨噬细胞(CFU-GM)和集落形成单位-高增殖潜能(CFU-HPP))。集落形成细胞的鉴定表明,胚胎干细胞分化成造血细胞,在限定条件下能扩大发展成确定的造血细胞谱系。
因此本发明的目的包括提供:
(a)上述获得造血细胞的各种方法;
(b)用这些方法衍生的各种细胞;和
(c)将这些衍生的细胞用于移植、输血和其它目的的各种方法。
在以下的优选实施例中,本发明的这些及其它一些目的和优点就更加显然。但为了对本发明更全面地进行评价,就应当关注这些权利要求。
发明详述
胚胎干细胞的培养
大部分试验都是用上述人ES细胞系H1,但以下的一些研究则是用上述ES细胞系H9(或H9.2)进行的,得到的结果类似。从初始分离和传代的细胞系衍生的细胞冷冻(液氮)原液取出这些细胞。在6孔培育板(Nunclon,Fisher)上培养H1 ES细胞。
首先用0.1%明胶溶液(Sigma)覆盖该培育板在37℃/5% CO2培养箱中放置1天或多天。此后,除去明胶溶液,再用辐照过的小鼠胚胎成纤维细胞(MEF)覆盖此培育板孔。这些MEF细胞是从12-13日胚龄小鼠胚胎(在由补充有10%胎牛血清(Hyclone或Harlan)、2mM 1-谷氨酰胺(GibcoBRL)和100单位/ml青霉素、100mg/ml链霉素(Sigma)的DMEM(GibcoBRL)构成的培养基中)衍生的。
在接种培养孔之前,用铯源发出的5500cGy辐照MEF细胞。以5×104细胞/ml、2.5ml/孔的密度添加MEF。然后将涂敷有MEF的平板在37℃/5%CO2培养箱中培养1天或多天,然后添加ES细胞。
以约5-8天的间隔将ES细胞在新MEF上传代。时间间隔取决于细胞密度和分化的形态表现。在传代时,除去ES细胞孔中的培养基,加入1-2ml含有1mg/ml胶原酶IV的DMEM(GibcoBRL)培养基。然后将此平板置于37℃/5%CO2中5-20分钟,直到开始形成ES细胞的集落。
然后用5ml移液管刮取平板孔上的ES细胞。将收获孔的内含物置于15ml锥形管(Fisher)中,以1000rpm离心5分钟。除去培养基,加入10ml新鲜培养基。ES细胞培养基由补充有20%血清替代物培养基(GibcoBRL)、8ng/mlbFGF(GibcoBRL)、1%非必要氨基酸溶液(GibcoBRL)、1mM 1-谷氨酰胺(GibcoBRL)和0.1M β-巯基乙醇的F12/DMEM(GibcoBRL)构成。
再次离心细胞(5分钟/1000rpm),除去培养基,以每孔2.5ml培养基的浓度悬浮(通常将15ml培养基接种于6个新孔中,1∶6传代)。然后用移液管将细胞移入上述用MEF覆盖的平板孔中。将细胞均匀地分布在各孔中,将平板置于37℃/5%CO2的培养箱中。
如果在细胞传代前就有表现分化形态的ES细胞集落,就用玻璃吸液管轻柔地将这些集落取出。操作是在解剖显微镜下观察进行的。除去已分化的细胞后,将剩下的集落进行上述传代。
传代后,对各孔的ES细胞以24-48小时间隔补加新鲜培养基培养。除去各孔的培养基,分别加入2.5ml新鲜的ES培养基。ES细胞的所有加料和传代都是在无菌环境下进行的。
ES细胞的分化
为了促进人ES细胞向造血系分化,按以上所述的方法收获ES细胞。然后将细胞接种于涂有哺乳动物基质细胞的6孔平板上。在一项试验中,我们采用上述经2500cGy辐射过的C166细胞。C166细胞最初是从12日胚龄的小鼠胚胎卵黄囊获得的,由Dr.Robert Auerbach(UW-Madison)惠赠。
在另一试验中,是用S17细胞。它们最初是从小鼠骨髓得到的,由Dr.Kenneth Dorshkind (当时在UC-Riverside,现在在UCLA)惠赠。
以1×105个细胞/ml,2.5ml/孔的密度接种C166或S17细胞。然后让接种S17或C166细胞的ES细胞,在补充有20%胎牛血清(Hyclone)、1%非必要氨基酸溶液、0.1M β-巯基乙醇和1mM 1-谷氨酰胺的DMEM(GibcoBRL)构成的培养基中生长。以24-72小时的间隔,将新鲜的这种培养基置于各孔中。对合适培养基的选择而言,虽然补充有特定的基质细胞,也只需要提供细胞生长所需的常规条件。
在接种S17或C166细胞上的3-7天后,ES细胞开始表现出分化,它们没有与在MEF喂养细胞上维持的未分化ES细胞相同均匀的外表。ES细胞的集落开始形成多种不同的细胞类型。这些集落中的一些区域表现为由卵石形态的细胞构成,表明是早期祖代造血细胞。
与血液相关的细胞的确定
一种确定有合适造血细胞存在与否的方法是在含有半固体甲基纤维素的培养基中分析造血集落形成细胞(CFC)。此时,让ES细胞在C166或S17细胞上分化2-3星期(如上所述)。然后除去培养基,加入2.5ml无钙和镁的磷酸盐缓冲盐水(PBS),2-5分钟后除去,加入1.5ml胰蛋白酶(0.125%)-EDTA(1mM)培养基。
将细胞置于37℃/5%CO2中10分钟。此后,集落开始分离。用移液管吸取和刮擦孔进一步将这些细胞分离。将这些细胞置于15ml锥形管中,在1000rpm离心5分钟,除去培养基,加入10ml新鲜培养基(DMEM+10%FBS+1-谷氨酰胺+青霉素/链霉素),再次离心。然后将细胞悬浮于5ml培养基中,用100mMnytex过滤器过滤除去聚团细胞。
另用5ml培养基洗涤此过滤器。然后将分离的/过滤的细胞在血细胞计数器上计数,并将1×106(通常,但不必总是如此多)细胞置于新的15ml锥形管中。然后将这些细胞离心,除去培养基,加入由IMDM(GibcoBRL)(补充有2%胎牛血清(Hyclone))构成的培养基。将细胞离心,除去培养基再加入250μl培养基(IMDM+2%FBS)。
根据特定的测试条件,将这些细胞加入2.5mlMethocult GF+H4435培养基(StemCell Technologies)中。该培养基由1.0%甲基纤维素构成,补充有30%FBS、20ng/ml IL-3、20ng/ml IL-6、50ng/ml干细胞因子、3单位/ml红细胞生成素、20ng/ml GM-CSF、20ng/ml G-CSF、2mM 1-谷氨酰胺、0.1mM b-巯基乙醇、1%胎牛血清白蛋白。然后剧烈旋转搅拌甲基纤维素中的细胞,然后将1.1ml此混合物接种于P35塑料皿(Stem Cell Technologies)上,在此皿上均匀涂布,并置于37℃/5%CO2中。
各样品一式两份按标准涂板,通常为4×105个细胞/平板。14-21天后,在显微镜下分析平板上造血集落的存在与否。通过与集落图谱(StemCellTechnologies)或书(造血细胞的培养,RI Freshney,IB Pragnell,MG Freshney编辑,Wiley-Liss,Inc,1994)比较来鉴定集落。将集落鉴定为以下情况之一:集落形成单位-红细胞(CFU-E)、母细胞形成单位-红细胞(BFU-E)、集落形成单位-巨噬细胞(CFU-M)、集落形成单位-粒细胞/巨噬细胞(CFU-GM)或集落形成单位-高增殖潜能(CFU-HPP)。
也可用流式细胞术鉴定是否存在所选的造血细胞。通过流式细胞计术可以寻找特定的细胞表面抗原。如上所述,用胰蛋白酶/EDTA收获在S17细胞或C166细胞上分化14-21天的ES细胞(如上所述),并通过100mM nytex滤器。在血细胞计数器上计数过滤的细胞,然后等份地加入15×75塑料管(Fisher)中,约1×105个细胞/管。然后离心细胞,除去培养基,加入2-3mlFACS培养基。(FACS培养基为含有0.5%BSA(Sigma)、0.1%叠氮化钠(Sigma)的PBS)。
再次离心细胞,并除去培养基。然后,以供应商推荐的浓度在这些孔中加入与荧光标记物(FITC或PE)直接连接的抗体。用以下抗体分析细胞:CD34-FITC(Immunotech)、CD45-PE(Pharmingen)。将IgG1-FITC和IgG1-PE用作细胞非特异性染色的同型对照。在冰浴上用合适的抗体培养这些细胞约30分钟,用2-3ml FACS培养基洗涤1-2次,然后悬浮于约0.5ml FACS培养基中。
然后按制造商说明用FACScan(Becton Dickinson)分析标记有抗体的细胞。加入二碘化丙锭(1mg/ml溶液,每管添加5μl)或7-AAD(Calbiochem)(0.2mg/ml,5μl/管),来测定死细胞的存在。用PC Lysis或Cellquest软件进行分析。
用以下试验方法来分析由免疫组织化学(IHC)的抗原表达。此时,如上述用胰蛋白酶/EDTA收获分化的与C166或S17(如上述)共培养的ES细胞。以约1×104-1×105浓度,将细胞悬浮于补充有10%FBS的DMEM培养基中。然后用Cytospin II离心机(Shanndon)将1×103-1×104个细胞离心到载玻片(Superfrost/plus,Fisher)上,得到这些细胞的“Cytospin”制备物。
然后用冷丙酮固定这些载玻片,在-20℃冷冻保藏。载玻片经室温解冻后进行IHC染色,用蜡笔(DAKO)勾画出细胞团。然后如下用Vectastain ABC试剂盒(Vector Laboratories,Burlingame,CA)将细胞染色,所有培养都是在室温中进行的。在细胞上加入100-200μl PBS,5分钟后除去。然后在细胞上加入Vectastain封阻抗体溶液(马血清)15分钟。然后将这些细胞印吸干燥,加入100-200μl初级抗体溶液。初级抗体是:IgGl(1μg/样品,Sigma),抗-CD34(0.5μg/样品,Immunotech)、抗-CD45(1μg/样品,DAKO)、抗-I类(1μg/样品,Dr.Paul Leibson,Mayo Clinic馈赠)、抗-CD14(1μg/样品,Pharmingen)、抗-CD31(1μg/样品,Pharmingen)。
加入初级抗体30分钟,然后加入PBS 10分钟。随后,加入经生物素酰化的抗-IgG抗体(Vectastain试剂盒,溶液B)30分钟,随后加入PBS 10分钟。室温加入Vectastain ABC溶液30分钟后,加入PBS10分钟。然后加入DAB溶液(Vectastain)5分钟,然后用自来水流冲洗10分钟。在一些试验中,随后用Gill苏木精溶液(Vector labs)复染色这些载玻片3分钟,再用自来水冲洗10分钟。然后将这些载玻片风干。阳性细胞染色为褐色。
2-3周后,在混合的细胞群体中证明有CD34+(约1%)。更重要的是,当收获、分离细胞并接种于甲基纤维素(半-固体)培养物时,分化的ES细胞显示生长成造血集落。
移植
目前造血细胞移植在临床上主要用于已接受高剂量化疗(治疗恶性肿瘤)的患者。这些患者通常接受自身或异体来源的造血细胞的多相混合物。人ES衍生的造血干细胞则至少可提供更同质性的细胞群体,用于造血细胞的移植。
另外,如上所述,如今可以控制移植的MHC特性,从而就有可能治疗各种自体免疫疾病。例如,造血干细胞(HSCs)和次级谱系(如用于糖尿病的朗格罕氏体(pancreatic islet)或用于多发性硬化的少突神经胶质细胞)都可以从同一亲代ES细胞系衍生。有了这两种细胞谱系,就可通过完全同种异体的造血细胞移植(HCT)首先产生造血嵌合体。已建立的嵌合状态可以让接受者的免疫系统将以后移植的次级细胞类型(如朗格罕氏体或少突神经胶质细胞)“视为”“自身”的,而不会被排斥。
例如,从小鼠ES细胞已获得少突神经胶质细胞(O.Brustle等人,285 Science754-6(1999))作为心肌细胞(M.Klug等人,98 J.Clin.Invest.216-224(1996))。
这种产生造血嵌合体的方法也能促进对移植组织的接受(除自身免疫以外的原因)。此时,接受同种异体移植造血干细胞的小鼠不会排斥具有相同遗传背景的其它组织(作为造血细胞),但依旧排斥第三方的移植物。参见K.Gandy等人,65 Transplantation 295-304(1998)。
除动物研究以外,现有一个临床案例报道了先前接受造血细胞移植的患者后来需要实体器官(肾脏)移植。在这些情况中,由先前提供骨髓移植的同一人的肾脏移植,在免疫学上是可接受的,不会再发生免疫抑制作用,参见T.Spitzer等人,68 Transplantation 480-484(1999)。
对犬类模型进行的研究和最近对人体作的一些临床试验表明可用更温和的不施行骨髓部分切除术(myeloablative)的条件疗法(conditioning regimen)更好地让宿主作好准备以接受同种异体的HCT。此时,只有中等剂量的全身辐照和短程的免疫抑制可用于制备接受同种异体HCT的宿主。
虽然以上已描述了一些优选的实施例,但本领域技术人员可以正确评价在本发明的范围内还可进行其它一些改变。例如,虽选择采用两种特定基质类型的细胞,但还有许多其它细胞也是适用的。例如,一种已公开可获得的基质细胞系是M2-10B4细胞系,其ATCC登录号为CRL-1972。
另外,以上描述侧重于产生红细胞和骨髓的前体,但采用上述各种方法还可以批量获得其它多种多样的感兴趣的与血液相关的细胞。参见美国专利No.5,914,268。因此,只有权利要求可以用来判断本发明的范围。
工业应用
本发明提供可用于移植、研究和其它目的的与血液相关的细胞。
Claims (9)
1.一种获得人造血细胞的方法,其特征在于,所述的方法包括将人胚胎干细胞培养物与哺乳动物的造血基质细胞接触,从而制备人造血细胞。
2.如权利要求1所述的方法,其特征在于,至少部分用所述方法产生的人造血细胞是CD34+。
3.如权利要求1所述的方法,其特征在于,至少有部分用所述方法产生的人造血细胞可在甲基纤维素培养物上形成造血细胞集落形成单位。
4.如权利要求1所述的方法,其特征在于,所述的基质细胞选自骨髓细胞和胚胎卵黄囊细胞。
5.一种获得人造血细胞的方法,其特征在于,所述的方法包括体外将人胚胎干细胞培养物与哺乳动物基质细胞接触,从而产生人造血细胞,其中至少部分用所述方法产生的人造血细胞可在甲基纤维素培养物上形成红细胞系母细胞形成单位。
6.如权利要求5所述的方法,其特征在于,至少部分用所述方法产生的人造血细胞是CD34+。
7.一种将人细胞移植入人类受体宿主的方法,其特征在于,所述的方法包括如下步骤:
获得在体外从胚胎干细胞培养物衍生的人造血细胞;
获得除造血细胞以外的所选人细胞,所选的非造血系细胞具有与造血细胞相容的主要组织相容性复合物;以及
将造血细胞和所选的人非造血系细胞一起移植入人类宿主。
8.如权利要求7所述的方法,其特征在于,所述的所选人细胞是人朗格罕氏体。
9.如权利要求7所述的方法,其特征在于,所述的所选人细胞是人少突神经胶质细胞。
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US09/435,578 US6280718B1 (en) | 1999-11-08 | 1999-11-08 | Hematopoietic differentiation of human pluripotent embryonic stem cells |
US09/435,578 | 1999-11-08 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN1387565A true CN1387565A (zh) | 2002-12-25 |
CN1228443C CN1228443C (zh) | 2005-11-23 |
Family
ID=23728955
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CNB008153264A Expired - Lifetime CN1228443C (zh) | 1999-11-08 | 2000-08-25 | 人胚胎干细胞的造血分化 |
Country Status (13)
Country | Link |
---|---|
US (3) | US6280718B1 (zh) |
EP (1) | EP1228194A1 (zh) |
JP (3) | JP2003513664A (zh) |
KR (2) | KR20070047850A (zh) |
CN (1) | CN1228443C (zh) |
AU (1) | AU784928B2 (zh) |
BR (1) | BR0015374A (zh) |
CA (1) | CA2390281C (zh) |
IL (2) | IL149387A0 (zh) |
IS (1) | IS6373A (zh) |
NO (1) | NO20022180L (zh) |
SE (1) | SE526490C2 (zh) |
WO (1) | WO2001034776A1 (zh) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN103740642A (zh) * | 2014-01-28 | 2014-04-23 | 娄彩玲 | 一种生产人红细胞的方法 |
Families Citing this family (182)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7410798B2 (en) * | 2001-01-10 | 2008-08-12 | Geron Corporation | Culture system for rapid expansion of human embryonic stem cells |
IL142748A0 (en) * | 1998-11-09 | 2002-03-10 | Univ Monash | Embryonic stem cells |
US10638734B2 (en) | 2004-01-05 | 2020-05-05 | Abt Holding Company | Multipotent adult stem cells, sources thereof, methods of obtaining and maintaining same, methods of differentiation thereof, methods of use thereof and cells derived thereof |
US8252280B1 (en) | 1999-08-05 | 2012-08-28 | Regents Of The University Of Minnesota | MAPC generation of muscle |
US7015037B1 (en) | 1999-08-05 | 2006-03-21 | Regents Of The University Of Minnesota | Multiponent adult stem cells and methods for isolation |
US20030129745A1 (en) | 1999-10-28 | 2003-07-10 | Robl James M. | Gynogenetic or androgenetic production of pluripotent cells and cell lines, and use thereof to produce differentiated cells and tissues |
US6280718B1 (en) * | 1999-11-08 | 2001-08-28 | Wisconsin Alumni Reasearch Foundation | Hematopoietic differentiation of human pluripotent embryonic stem cells |
US6602711B1 (en) * | 2000-02-21 | 2003-08-05 | Wisconsin Alumni Research Foundation | Method of making embryoid bodies from primate embryonic stem cells |
US6534052B1 (en) | 2000-09-05 | 2003-03-18 | Yong-Fu Xiao | Cardiac function comprising implantation of embryonic stem cell in which differentiation has been initiated |
US6607720B1 (en) | 2000-09-05 | 2003-08-19 | Yong-Fu Xiao | Genetically altered mammalian embryonic stem cells, their living progeny, and their therapeutic application for improving cardiac function after myocardial infarction |
US7311905B2 (en) | 2002-02-13 | 2007-12-25 | Anthrogenesis Corporation | Embryonic-like stem cells derived from post-partum mammalian placenta, and uses and methods of treatment using said cells |
WO2002046373A1 (en) | 2000-12-06 | 2002-06-13 | Hariri Robert J | Method of collecting placental stem cells |
JP2005503759A (ja) * | 2001-01-24 | 2005-02-10 | アメリカ合衆国 | 幹細胞の膵臓内分泌細胞への分化方法 |
EP2316919B1 (en) * | 2001-02-14 | 2015-10-07 | Anthrogenesis Corporation | Post-partum mammalian placenta, its use and placental stem cells therefrom |
EP1367899A4 (en) * | 2001-02-14 | 2004-07-28 | Leo T Furcht | TOTIPOTENT ADULT STEM CELLS, SOURCES OF SUCH CELLS, METHODS FOR OBTAINING AND MAINTAINING SAME, METHODS FOR DIFFERENTIATING THESE CELLS, METHODS OF USING SAME, AND CELLS DERIVED FROM THE ABOVE-MENTIONED CELLS |
US20030211605A1 (en) * | 2001-05-01 | 2003-11-13 | Lee Sang-Hun | Derivation of midbrain dopaminergic neurons from embryonic stem cells |
AU2002317039B2 (en) * | 2001-07-24 | 2007-10-04 | Es Cell International Pte Ltd | Methods of inducing differentiation of stem cells |
JP2005500847A (ja) * | 2001-08-24 | 2005-01-13 | アドバンスド セル テクノロジー、インコーポレイテッド | 分化誘導薬の同定のためのスクリーニング検定及び細胞治療用の分化細胞の調製 |
DE10144326B4 (de) * | 2001-09-10 | 2005-09-22 | Siemens Ag | Verfahren und System zur Überwachung eines Reifenluftdrucks |
US6759244B2 (en) * | 2001-11-08 | 2004-07-06 | Art Institute Of New York And New Jersey, Inc. | Composite blastocysts (CBs) from aggregates of dissociated cells of non-viable pre-embryos |
EP1451300A4 (en) * | 2001-11-09 | 2007-01-10 | Artecel Sciences Inc | METHODS AND COMPOSITIONS IN WHICH STROMAL CELLS ARE USED TO SUPPORT EMBRYONIC AND ADULT STEM CELLS |
AU2012258384B2 (en) * | 2001-12-07 | 2016-04-21 | Asterias Biotherapeutics, Inc. | Hematopoietic cells from human embryonic stem cells |
US7799324B2 (en) * | 2001-12-07 | 2010-09-21 | Geron Corporation | Using undifferentiated embryonic stem cells to control the immune system |
US20040224403A1 (en) * | 2001-12-07 | 2004-11-11 | Robarts Research Institute | Reconstituting hematopoietic cell function using human embryonic stem cells |
US20030153082A1 (en) * | 2001-12-07 | 2003-08-14 | The John P. Robarts Research Institute | Hematopoietic cells from human embryonic stem cells |
AU2016206280B2 (en) * | 2001-12-07 | 2018-05-17 | Asterias Biotherapeutics, Inc. | Hematopoietic cells from human embryonic stem cells |
WO2003060083A2 (en) * | 2002-01-15 | 2003-07-24 | Advanced Cell Technology, Inc. | Cloning b and t lymphocytes |
US20050090004A1 (en) * | 2003-01-16 | 2005-04-28 | Sayre Chauncey B. | Stem cell maturation for all tissue lines |
US20050170506A1 (en) * | 2002-01-16 | 2005-08-04 | Primegen Biotech Llc | Therapeutic reprogramming, hybrid stem cells and maturation |
US20030134422A1 (en) * | 2002-01-16 | 2003-07-17 | Sayre Chauncey Bigelow | Stem cell maturation for all tissue lines |
WO2003080806A2 (en) * | 2002-03-18 | 2003-10-02 | National Jewish Medical And Research Center | Method for production of neutrophils and uses therefor |
US7498171B2 (en) * | 2002-04-12 | 2009-03-03 | Anthrogenesis Corporation | Modulation of stem and progenitor cell differentiation, assays, and uses thereof |
GB0210741D0 (en) * | 2002-05-10 | 2002-06-19 | Medical Res Council | Methods of therapy |
US20040091936A1 (en) | 2002-05-24 | 2004-05-13 | Michael West | Bank of stem cells for producing cells for transplantation having HLA antigens matching those of transplant recipients, and methods for making and using such a stem cell bank |
CA2505598A1 (en) | 2002-05-24 | 2003-12-04 | Advanced Cell Technology, Inc. | A bank of stem cells for transplantation |
CN1668733A (zh) * | 2002-05-30 | 2005-09-14 | 细胞基因公司 | 利用jnk或mkk抑制剂调节细胞分化并治疗骨髓增生异常和脊髓发育不良综合症的方法 |
EP1534068A4 (en) * | 2002-08-08 | 2006-08-23 | Univ Georgia Res Found | COMPOSITIONS AND METHODS FOR NEURONAL DIFFERENTIATION OF HUMAN EMBRYONIC STEM CELLS |
US20040219563A1 (en) * | 2002-10-16 | 2004-11-04 | Michael West | Method using gene trapped stem cells for making pathways of stem cell differentiation and making and isolating differentiated cells |
GB0224415D0 (en) * | 2002-10-21 | 2002-11-27 | Medical Res Council | Compositions |
WO2004047770A2 (en) | 2002-11-26 | 2004-06-10 | Anthrogenesis Corporation | Cytotherapeutics, cytotherapeutic units and methods for treatments using them |
EP1567639A4 (en) * | 2002-12-05 | 2005-12-21 | Technion Res & Dev Foundation | CULTURE OF HUMAN PANCREATIC ISLANDS AND USES THEREOF |
US20040110286A1 (en) * | 2002-12-06 | 2004-06-10 | The John P. Robarts Research Institute | Method for making hematopoietic cells |
NZ542127A (en) * | 2003-02-13 | 2008-04-30 | Anthrogenesis Corp | Use of umbilical cord blood to treat individuals having a disease, disorder or condition |
US20060177929A1 (en) * | 2003-03-24 | 2006-08-10 | Klug Christopher A | Regulation of self-renewal in stem cells |
US8252588B2 (en) | 2003-04-08 | 2012-08-28 | Yeda Research And Development Co. Ltd. | Stem cells having increased sensitivity to SDF-1 and methods of generating and using same |
FR2853551B1 (fr) | 2003-04-09 | 2006-08-04 | Lab Francais Du Fractionnement | Formulation stabilisante pour compositions d'immunoglobulines g sous forme liquide et sous forme lyophilisee |
AU2004242091C1 (en) * | 2003-05-07 | 2009-12-24 | La Jolla Institute For Molecular Medicine | Administration of hyaluronic acid to enhance the function of transplanted stem cells |
NZ547105A (en) * | 2003-10-16 | 2009-02-28 | Univ Edinburgh | Control of ES cell self-renewal and lineage specification, and medium therefor |
IL158868A0 (en) * | 2003-11-13 | 2004-05-12 | Yeda Res & Dev | Methods of generating and using stem cells enriched with immature primitive progenitor |
WO2005049812A1 (en) * | 2003-11-19 | 2005-06-02 | Australian Stem Cell Centre Limited | Methods for producing blood products from pluripotent cells in cell culture |
US20070269412A1 (en) * | 2003-12-02 | 2007-11-22 | Celavie Biosciences, Llc | Pluripotent cells |
ES2579804T3 (es) * | 2003-12-02 | 2016-08-16 | Celavie Biosciences, Llc | Composiciones y métodos para la propagación de células progenitoras neurales |
WO2005080551A2 (en) * | 2004-02-12 | 2005-09-01 | University Of Newcastle Upon Tyne | Stem cells |
US20050232905A1 (en) * | 2004-03-26 | 2005-10-20 | Yeh Edward T | Use of peripheral blood cells for cardiac regeneration |
US20050221482A1 (en) * | 2004-03-31 | 2005-10-06 | Burt Richard K | Methods and compositions for obtaining hematopoietic stem cells derived from embryonic stem cells and uses thereof |
EP1747265B1 (en) * | 2004-04-23 | 2011-04-20 | BioE LLC | Multi-lineage progenitor cells |
US7622108B2 (en) * | 2004-04-23 | 2009-11-24 | Bioe, Inc. | Multi-lineage progenitor cells |
WO2005113751A1 (en) | 2004-05-14 | 2005-12-01 | Becton, Dickinson And Company | Cell culture environments for the serum-free expansion of mesenchymal stem cells |
WO2006017370A2 (en) | 2004-07-13 | 2006-02-16 | Geron Corporation | Medium for growing human embryonic stem cells |
CA2504451A1 (en) * | 2004-08-10 | 2006-02-10 | Geron Corporation | Dendritic cell vaccines for treating cancer made from embryonic stem cells |
US8354277B2 (en) * | 2004-10-12 | 2013-01-15 | Technion Research & Development Foundation Ltd. | Isolated primate embryonic cells derived from extended blastocysts |
AU2005302258B2 (en) * | 2004-11-01 | 2010-10-21 | Wisconsin Alumni Research Foundation | Platelets from stem cells |
US20070077654A1 (en) * | 2004-11-01 | 2007-04-05 | Thomson James A | Platelets from stem cells |
US20060263879A1 (en) * | 2004-12-30 | 2006-11-23 | Stemlifeline, Inc. | Methods and systems relating to embryonic stem cell lines |
US20060275899A1 (en) * | 2004-12-30 | 2006-12-07 | Stemlifeline, Inc. | Methods and compositions relating to embryonic stem cell lines |
WO2006086746A2 (en) * | 2005-02-09 | 2006-08-17 | Burnham Institute For Medical Research | Homogeneous neural precursor cells |
CA2607060A1 (en) | 2005-05-04 | 2006-11-09 | Australian Stem Cell Centre Limited | Selecting, culturing and creating lineage committed hematopoietic stem cells |
US8034613B2 (en) | 2005-06-01 | 2011-10-11 | Wisconsin Alumni Research Foundation | Multipotent lymphohematopoietic progenitor cells |
AU2006252576B2 (en) * | 2005-06-01 | 2011-01-20 | Wisconsin Alumni Research Foundation | Method of forming dendritic cells from embryonic stem cells |
CN107189980B (zh) | 2005-06-22 | 2021-07-09 | 阿斯特利亚斯生物治疗股份公司 | 人胚胎干细胞的悬浮培养物 |
CN101228264B (zh) | 2005-06-22 | 2017-12-26 | 阿斯特利亚斯生物治疗股份公司 | 使灵长类多能干细胞分化成心肌细胞系细胞 |
JP4268209B2 (ja) * | 2005-07-20 | 2009-05-27 | ソウル ナショナル ユニバーシティ インダストリー ファウンデーション | 子宮内膜細胞を用いた造血幹細胞または前駆細胞の培養及び増殖方法 |
NZ612132A (en) | 2005-10-13 | 2015-01-30 | Anthrogenesis Corp | Immunomodulation using placental stem cells |
US8278104B2 (en) | 2005-12-13 | 2012-10-02 | Kyoto University | Induced pluripotent stem cells produced with Oct3/4, Klf4 and Sox2 |
US8129187B2 (en) | 2005-12-13 | 2012-03-06 | Kyoto University | Somatic cell reprogramming by retroviral vectors encoding Oct3/4. Klf4, c-Myc and Sox2 |
BRPI0619794B8 (pt) | 2005-12-13 | 2022-06-14 | Univ Kyoto | Uso de um fator de reprogramação, agente para a preparação de uma célula-tronco pluripotente induzida a partir de uma célula somática e métodos para preparar uma célula- tronco pluripotente induzida método e para preparar uma célula somática e uso de células-tronco pluripotentes induzidas |
EP1976978A2 (en) | 2005-12-29 | 2008-10-08 | Anthrogenesis Corporation | Co-culture of placental stem cells and stem cells from a second source |
CN108559725A (zh) | 2005-12-29 | 2018-09-21 | 人类起源公司 | 胎盘干细胞群 |
EP2019858B1 (en) * | 2006-04-17 | 2012-06-13 | BioE LLC | Differentiation of multi-lineage progenitor cells to respiratory epithelial cells |
US8809052B2 (en) * | 2006-08-28 | 2014-08-19 | Yeda Research And Development Co. Ltd. | Methods of generating mature oligodendrocytes |
US20080108044A1 (en) * | 2006-11-08 | 2008-05-08 | Deepika Rajesh | In vitro differentiation of hematopoietic cells from primate embryonic stem cells |
EP2087101A2 (en) * | 2006-11-24 | 2009-08-12 | Regents of the University of Minnesota | Endodermal progenitor cells |
US7883698B2 (en) * | 2007-01-17 | 2011-02-08 | Maria Michejda | Isolation and preservation of fetal hematopoietic and mesencymal system cells from non-controversial materials and/or tissues resulting from miscarriages and methods of therapeutic use |
EP3103462A1 (en) | 2007-02-12 | 2016-12-14 | Anthrogenesis Corporation | Treatment of inflammatory diseases using placental stem cells |
JP2008307007A (ja) | 2007-06-15 | 2008-12-25 | Bayer Schering Pharma Ag | 出生後のヒト組織由来未分化幹細胞から誘導したヒト多能性幹細胞 |
US9029147B2 (en) * | 2007-06-15 | 2015-05-12 | Massachusetts Institute Of Technology | Methods and compositions for enhanced differentiation from embryonic stem cells |
US9213999B2 (en) | 2007-06-15 | 2015-12-15 | Kyoto University | Providing iPSCs to a customer |
CA2693827A1 (en) * | 2007-07-25 | 2009-01-29 | Bioe, Inc. | Differentiation of multi-lineage progenitor cells to chondrocytes |
KR20190132556A (ko) | 2007-09-28 | 2019-11-27 | 안트로제네시스 코포레이션 | 인간 태반 관류액 및 인간 태반-유래 중간체 천연 킬러 세포를 사용한 종양 억제 방법 |
KR101532442B1 (ko) | 2007-12-10 | 2015-06-29 | 고쿠리츠 다이가쿠 호진 교토 다이가쿠 | 효율적인 핵 초기화 방법 |
US9683232B2 (en) | 2007-12-10 | 2017-06-20 | Kyoto University | Efficient method for nuclear reprogramming |
WO2009134409A2 (en) * | 2008-04-30 | 2009-11-05 | Sanbio, Inc. | Neural regenerating cells with alterations in dna methylation |
ES2722198T3 (es) | 2008-05-02 | 2019-08-08 | Univ Kyoto | Método de reprogramación nuclear |
CA2724839A1 (en) * | 2008-05-21 | 2009-11-26 | Bioe Llc | Differentiation of multi-lineage progenitor cells to pancreatic cells |
NZ591294A (en) | 2008-08-20 | 2012-10-26 | Anthrogenesis Corp | Treatment of stroke using isolated placental cells |
MX339624B (es) | 2008-08-20 | 2016-06-02 | Anthrogenesis Corp | Composiciones mejoradas de celulas y metodos para preparar las mismas. |
AU2009283161A1 (en) | 2008-08-22 | 2010-02-25 | Anthrogenesis Corporation | Methods and compositions for treatment of bone defects with placental cell populations |
JP5869342B2 (ja) | 2008-11-19 | 2016-02-24 | アンスロジェネシス コーポレーション | 羊膜由来接着細胞 |
US20100209399A1 (en) * | 2009-02-13 | 2010-08-19 | Celavie Biosciences, Llc | Brain-derived stem cells for repair of musculoskeletal system in vertebrate subjects |
JP5717030B2 (ja) | 2009-02-24 | 2015-05-13 | 学校法人金沢医科大学 | 有核赤血球の脱核方法及び脱核誘導剤 |
WO2011005326A1 (en) | 2009-07-09 | 2011-01-13 | Massachusetts Institute Of Technology | Methods and compositions for increased safety of stem cell-derived populations |
ES2550202T3 (es) * | 2009-08-03 | 2015-11-05 | Recombinetics, Inc. | Métodos y composiciones para la modificación dirigida de genes |
JP5902092B2 (ja) | 2009-10-19 | 2016-04-13 | セルラー ダイナミクス インターナショナル, インコーポレイテッド | 心筋細胞の生成 |
CA2787992A1 (en) | 2010-01-26 | 2011-08-04 | Anthrogenesis Corporation | Treatment of bone-related cancers using placental stem cells |
TW201703777A (zh) | 2010-04-07 | 2017-02-01 | 安瑟吉納西斯公司 | 利用胎盤幹細胞之血管新生 |
US8562973B2 (en) | 2010-04-08 | 2013-10-22 | Anthrogenesis Corporation | Treatment of sarcoidosis using placental stem cells |
CA2802087A1 (en) | 2010-06-15 | 2011-12-22 | Cellular Dynamics International, Inc. | A compendium of ready-built stem cell models for interrogation of biological response |
MX342995B (es) | 2010-07-13 | 2016-10-21 | Anthrogenesis Corp | Métodos de generar células asesinas naturales. |
WO2012018933A2 (en) | 2010-08-04 | 2012-02-09 | Cellular Dynamics International, Inc. | Reprogramming immortalized b cells |
US9057734B2 (en) | 2010-08-23 | 2015-06-16 | President And Fellows Of Harvard College | Optogenetic probes for measuring membrane potential |
WO2012048275A2 (en) | 2010-10-08 | 2012-04-12 | Caridianbct, Inc. | Configurable methods and systems of growing and harvesting cells in a hollow fiber bioreactor system |
EP2630232A4 (en) | 2010-10-22 | 2014-04-02 | Biotime Inc | METHOD FOR MODIFYING TRANSCRIPTIONAL REGULATORY NETWORKS IN STEM CELLS |
AU2011352036A1 (en) | 2010-12-31 | 2013-07-18 | Anthrogenesis Corporation | Enhancement of placental stem cell potency using modulatory RNA molecules |
EP2801377B1 (en) | 2011-03-04 | 2019-08-07 | The Regents of The University of California | Hydrogel comprising cells for local release of growth factors to mediate motor recovery after stroke |
AU2012236707B2 (en) | 2011-03-29 | 2017-07-20 | Asterias Biotherapeutics, Inc. | Enriched populations of cardiomyocyte lineage cells from pluripotent stem cells |
CA2832356C (en) | 2011-04-06 | 2017-12-19 | Sanbio, Inc. | Methods and compositions for modulating peripheral immune function |
CN113559126A (zh) | 2011-06-01 | 2021-10-29 | 人类起源公司 | 利用胎盘干细胞治疗疼痛 |
WO2013010045A1 (en) | 2011-07-12 | 2013-01-17 | Biotime Inc. | Novel methods and formulations for orthopedic cell therapy |
WO2013028684A1 (en) | 2011-08-23 | 2013-02-28 | Wisconsin Alumni Research Foundation | Angiohematopoietic progenitor cells |
US9925221B2 (en) | 2011-09-09 | 2018-03-27 | Celularity, Inc. | Treatment of amyotrophic lateral sclerosis using placental stem cells |
EP2594295A1 (en) | 2011-11-16 | 2013-05-22 | Servicio Andaluz De Salud | Nerve implants based on a compacted biomaterial containing cells |
US9447378B2 (en) | 2012-04-27 | 2016-09-20 | Massachusetts Institute Of Technology | Method for differentiating human embryonic stem cells into β-cells for the treatment of type I diabetes |
JP5432322B2 (ja) | 2012-05-08 | 2014-03-05 | 株式会社大塚製薬工場 | トレハロース含有肺塞栓形成予防用哺乳動物細胞懸濁液 |
US20140178988A1 (en) | 2012-10-08 | 2014-06-26 | Biotime, Inc. | Differentiated Progeny of Clonal Progenitor Cell Lines |
US9763983B2 (en) | 2013-02-05 | 2017-09-19 | Anthrogenesis Corporation | Natural killer cells from placenta |
EP2987852A4 (en) | 2013-04-17 | 2016-09-07 | Nissan Chemical Ind Ltd | MIDDLE COMPOSITION AND PROCESS FOR PRODUCING RED GLOBLES USING THE SAME |
CN105473134B (zh) | 2013-06-05 | 2021-04-27 | 再生疗法有限公司 | 用于哺乳动物物种中诱导性组织再生的组合物和方法 |
US9816070B2 (en) | 2013-06-14 | 2017-11-14 | Massachusetts Institute Of Technology | Articles and methods for stem cell differentiation |
RU2663793C2 (ru) | 2013-06-28 | 2018-08-09 | Оцука Фармасьютикал Фэктори, Инк. | Содержащий трегалозу и декстран раствор для трансплантации клеток млекопитающих |
JP6612227B2 (ja) | 2013-11-16 | 2019-11-27 | テルモ ビーシーティー、インコーポレーテッド | バイオリアクターにおける細胞増殖 |
US11078462B2 (en) | 2014-02-18 | 2021-08-03 | ReCyte Therapeutics, Inc. | Perivascular stromal cells from primate pluripotent stem cells |
EP3122866B1 (en) | 2014-03-25 | 2019-11-20 | Terumo BCT, Inc. | Passive replacement of media |
US10240127B2 (en) | 2014-07-03 | 2019-03-26 | ReCyte Therapeutics, Inc. | Exosomes from clonal progenitor cells |
JP6830059B2 (ja) | 2014-09-26 | 2021-02-17 | テルモ ビーシーティー、インコーポレーテッド | スケジュール化された細胞フィーディング |
JP6682446B2 (ja) | 2014-10-24 | 2020-04-15 | 大日本住友製薬株式会社 | 網膜組織の製造方法 |
US10286009B2 (en) * | 2015-05-16 | 2019-05-14 | Asterias Biotherapeutics, Inc. | Pluripotent stem cell-derived oligodendrocyte progenitor cells for the treatment of spinal cord injury |
WO2017004592A1 (en) | 2015-07-02 | 2017-01-05 | Terumo Bct, Inc. | Cell growth with mechanical stimuli |
US11649432B2 (en) | 2015-09-08 | 2023-05-16 | Sumitomo Pharma Co., Ltd. | Method for producing retinal pigment epithelial cells |
CA3007733A1 (en) | 2015-12-07 | 2017-06-15 | Biotime, Inc. | Methods for the re-derivation of diverse pluripotent stem cell-derived brown fat cells |
CN109069870B (zh) | 2016-02-24 | 2022-04-29 | 洛克菲勒大学 | 基于胚胎细胞的用于亨廷顿氏病的治疗候选物筛选系统、模型及它们的应用 |
WO2017173064A1 (en) | 2016-03-30 | 2017-10-05 | Asterias Biotherapeutics, Inc. | Oligodendrocyte progenitor cell compositions |
JP7034949B2 (ja) | 2016-05-25 | 2022-03-14 | テルモ ビーシーティー、インコーポレーテッド | 細胞の増殖 |
US11104874B2 (en) | 2016-06-07 | 2021-08-31 | Terumo Bct, Inc. | Coating a bioreactor |
US11685883B2 (en) | 2016-06-07 | 2023-06-27 | Terumo Bct, Inc. | Methods and systems for coating a cell growth surface |
JP7006943B2 (ja) | 2016-11-04 | 2022-01-24 | 国立大学法人 東京大学 | 間葉系細胞及び間葉系幹細胞の凍結保存用溶液、凍結物、及び凍結保存方法 |
JP7184283B2 (ja) | 2016-11-25 | 2022-12-06 | 国立研究開発法人理化学研究所 | 移植用細胞集団及びその製造方法 |
WO2018110159A1 (ja) | 2016-12-14 | 2018-06-21 | 株式会社大塚製薬工場 | 哺乳動物細胞凍結保存液 |
JP7007686B2 (ja) | 2017-03-08 | 2022-01-25 | 大日本住友製薬株式会社 | 網膜色素上皮細胞の製造方法 |
US11624046B2 (en) | 2017-03-31 | 2023-04-11 | Terumo Bct, Inc. | Cell expansion |
CN110612344B (zh) | 2017-03-31 | 2023-09-12 | 泰尔茂比司特公司 | 细胞扩增 |
WO2019017491A1 (ja) | 2017-07-20 | 2019-01-24 | 国立研究開発法人理化学研究所 | 神経組織の保存方法 |
EP3656852A4 (en) | 2017-07-20 | 2021-04-21 | Riken | RETINAL TISSUE MATURATION PROCESS CONTAINING A CONTINUOUS EPITHELIUM |
JP7162221B2 (ja) | 2017-09-08 | 2022-10-28 | 国立研究開発法人理化学研究所 | 網膜組織を含む細胞凝集体及びその製造方法 |
CA3075877A1 (en) | 2017-09-14 | 2019-03-21 | Riken | Method for producing retinal tissues |
US20200277571A1 (en) | 2017-09-14 | 2020-09-03 | Riken | Method for amplifying cone photoreceptors or rod photoreceptors using dorsalization signal transmitter or ventralization signal transmitter |
CA3083864A1 (en) | 2017-11-24 | 2019-05-31 | Sumitomo Chemical Company, Limited | Method for producing cell mass including pituitary tissue, and cell mass thereof |
JP7384671B2 (ja) | 2017-11-24 | 2023-11-21 | 住友化学株式会社 | 神経系細胞又は神経組織と非神経上皮組織とを含む細胞塊の製造方法及びその細胞塊 |
JP7414530B2 (ja) | 2018-02-19 | 2024-01-16 | 住友ファーマ株式会社 | 細胞凝集体、細胞凝集体の混合物及びそれらの製造方法 |
US20210308188A1 (en) | 2018-08-24 | 2021-10-07 | Sumitomo Chemical Company, Limited | Cell cluster including olfactory neuron or precursor cell thereof, and method for producing same |
SG11202102876XA (en) | 2018-09-28 | 2021-04-29 | Otsuka Pharma Factory Inc | Mammal cell preserving solution containing acarbose or stachyose |
JP7410518B2 (ja) | 2018-11-15 | 2024-01-10 | Jsr株式会社 | 脳オルガノイドの製造方法 |
US20220049220A1 (en) | 2018-12-20 | 2022-02-17 | Sumitomo Chemical Company, Limited | Embryonic erythroblast-containing cell population and method for producing same, cell culture composition, and compound test method |
CA3122791A1 (en) | 2018-12-28 | 2020-07-02 | Riken | Therapeutic drug for disease accompanied by disorders in retinal cells or retinal tissue |
SG11202107732XA (en) | 2019-01-23 | 2021-08-30 | Asterias Biotherapeutics Inc | Dorsally-derived oligodendrocyte progenitor cells from human pluripotent stem cells |
SG11202109855PA (en) | 2019-03-13 | 2021-10-28 | Sumitomo Dainippon Pharma Co Ltd | Method for evaluating quality of transplant neural retina, and transplant neural retina sheet |
WO2020218480A1 (ja) | 2019-04-26 | 2020-10-29 | 国立研究開発法人理化学研究所 | 神経網膜と網膜色素上皮細胞とハイドロゲルとを含む複合体及びその製造方法 |
SG11202111764RA (en) | 2019-04-26 | 2021-11-29 | Otsuka Pharma Factory Inc | Trehalose-containing liquid for mammalian cell preservation |
KR20220052946A (ko) | 2019-09-06 | 2022-04-28 | 각고호우징 게이오기주크 | 글리아 전구 세포를 포함하는 세포 응집체의 제조 방법 |
CA3162268A1 (en) | 2019-11-20 | 2021-05-25 | Sumitomo Pharma Co., Ltd. | Method for freezing neural cells |
EP4063495A4 (en) | 2019-11-20 | 2023-12-27 | Sumitomo Pharma Co., Ltd. | METHOD FOR FREEZING CELL Aggregates |
US20230310614A1 (en) | 2020-09-11 | 2023-10-05 | Sumitomo Pharma Co., Ltd. | Medium for Tissue for Transplantation |
WO2022054925A1 (ja) | 2020-09-11 | 2022-03-17 | 国立研究開発法人理化学研究所 | 神経網膜を含む細胞凝集体とマトリクスとを含む複合体及びその製造方法 |
TW202302839A (zh) | 2021-03-09 | 2023-01-16 | 國立研究開發法人理化學研究所 | 低免疫原性視網膜色素上皮細胞之製造方法 |
GB2619893A (en) | 2021-03-23 | 2023-12-20 | Terumo Bct Inc | Cell capture and expansion |
JPWO2022265086A1 (zh) | 2021-06-17 | 2022-12-22 | ||
WO2023039588A1 (en) | 2021-09-13 | 2023-03-16 | FUJIFILM Cellular Dynamics, Inc. | Methods for the production of committed cardiac progenitor cells |
WO2023049826A1 (en) | 2021-09-23 | 2023-03-30 | President And Fellows Of Harvard College | Genetically encoded voltage indicators and uses thereof |
CA3234334A1 (en) | 2021-09-30 | 2023-04-06 | Sumitomo Pharma Co., Ltd. | Cell aggregate including pituitary hormone-producing cells and method for producing same |
JPWO2023054396A1 (zh) | 2021-09-30 | 2023-04-06 | ||
CN118302517A (zh) | 2021-11-19 | 2024-07-05 | 国立研究开发法人理化学研究所 | 片状视网膜组织的制造方法 |
KR20240125943A (ko) | 2021-12-27 | 2024-08-20 | 스미토모 파마 가부시키가이샤 | 신경능 세포의 배양 방법 및 제조 방법 |
US20240139256A1 (en) | 2022-09-30 | 2024-05-02 | FUJIFILM Cellular Dynamics, Inc. | Methods for the production of cardiac fibroblasts |
Family Cites Families (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5635386A (en) * | 1989-06-15 | 1997-06-03 | The Regents Of The University Of Michigan | Methods for regulating the specific lineages of cells produced in a human hematopoietic cell culture |
NZ314644A (en) * | 1993-05-24 | 2000-11-24 | Immunex Corp | Use of flt3-ligands as a growth stimulator of stem cells in the transplantation of tissue |
US5914268A (en) | 1994-11-21 | 1999-06-22 | National Jewish Center For Immunology & Respiratory Medicine | Embryonic cell populations and methods to isolate such populations |
US5843780A (en) | 1995-01-20 | 1998-12-01 | Wisconsin Alumni Research Foundation | Primate embryonic stem cells |
IL128348A (en) | 1996-08-19 | 2008-08-07 | Univ Massachusetts | Method of producing embryonic or stem like cell lines by transplantation of cell nuclei from animal or mammal, such cells and uses thereof |
US6280718B1 (en) * | 1999-11-08 | 2001-08-28 | Wisconsin Alumni Reasearch Foundation | Hematopoietic differentiation of human pluripotent embryonic stem cells |
-
1999
- 1999-11-08 US US09/435,578 patent/US6280718B1/en not_active Expired - Lifetime
-
2000
- 2000-08-25 WO PCT/US2000/023469 patent/WO2001034776A1/en active IP Right Grant
- 2000-08-25 JP JP2001537473A patent/JP2003513664A/ja active Pending
- 2000-08-25 KR KR1020077008013A patent/KR20070047850A/ko active Search and Examination
- 2000-08-25 CA CA002390281A patent/CA2390281C/en not_active Expired - Lifetime
- 2000-08-25 IL IL14938700A patent/IL149387A0/xx active IP Right Grant
- 2000-08-25 AU AU69404/00A patent/AU784928B2/en not_active Expired
- 2000-08-25 BR BR0015374-5A patent/BR0015374A/pt not_active Application Discontinuation
- 2000-08-25 EP EP00957842A patent/EP1228194A1/en not_active Withdrawn
- 2000-08-25 CN CNB008153264A patent/CN1228443C/zh not_active Expired - Lifetime
- 2000-08-25 KR KR1020027005890A patent/KR20030022766A/ko not_active Application Discontinuation
-
2001
- 2001-08-27 US US09/940,175 patent/US6613568B2/en not_active Expired - Lifetime
-
2002
- 2002-04-28 IL IL149387A patent/IL149387A/en unknown
- 2002-05-03 SE SE0201328A patent/SE526490C2/sv unknown
- 2002-05-06 IS IS6373A patent/IS6373A/is unknown
- 2002-05-07 NO NO20022180A patent/NO20022180L/no not_active Application Discontinuation
-
2003
- 2003-08-29 US US10/652,468 patent/US20040043484A1/en not_active Abandoned
-
2009
- 2009-10-01 JP JP2009229464A patent/JP2010042011A/ja active Pending
-
2013
- 2013-10-07 JP JP2013210318A patent/JP2014000096A/ja active Pending
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN103740642A (zh) * | 2014-01-28 | 2014-04-23 | 娄彩玲 | 一种生产人红细胞的方法 |
Also Published As
Publication number | Publication date |
---|---|
IL149387A0 (en) | 2002-11-10 |
IS6373A (is) | 2002-05-06 |
US6280718B1 (en) | 2001-08-28 |
US20040043484A1 (en) | 2004-03-04 |
US6613568B2 (en) | 2003-09-02 |
WO2001034776A1 (en) | 2001-05-17 |
NO20022180L (no) | 2002-06-03 |
SE0201328L (sv) | 2002-07-05 |
SE526490C2 (sv) | 2005-09-27 |
JP2014000096A (ja) | 2014-01-09 |
AU6940400A (en) | 2001-06-06 |
US20020015694A1 (en) | 2002-02-07 |
EP1228194A1 (en) | 2002-08-07 |
KR20070047850A (ko) | 2007-05-07 |
AU784928B2 (en) | 2006-07-27 |
NO20022180D0 (no) | 2002-05-07 |
JP2003513664A (ja) | 2003-04-15 |
IL149387A (en) | 2008-08-07 |
CA2390281A1 (en) | 2001-05-17 |
SE0201328D0 (sv) | 2002-05-03 |
CN1228443C (zh) | 2005-11-23 |
BR0015374A (pt) | 2002-12-24 |
JP2010042011A (ja) | 2010-02-25 |
KR20030022766A (ko) | 2003-03-17 |
CA2390281C (en) | 2005-10-25 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN1228443C (zh) | 人胚胎干细胞的造血分化 | |
US5965436A (en) | Method of isolating mesenchymal stem cells associated with isolated megakaryocytes by isolating megakaryocytes | |
Raynaud et al. | Comprehensive characterization of mesenchymal stem cells from human placenta and fetal membrane and their response to osteoactivin stimulation | |
Perry et al. | L-selectin defines a bone marrow analog to the thymic early T-lineage progenitor | |
US8486700B2 (en) | Multiple mesodermal lineage differentiation potentials for adipose tissue-derived stromal cells and uses thereof | |
Deasy et al. | Long-term self-renewal of postnatal muscle-derived stem cells | |
Huss | Perspectives on the morphology and biology of CD34-negative stem cells | |
KR20080015033A (ko) | 배아 줄기 세포로부터 가지 세포를 형성하는 방법 | |
WO2008056963A1 (en) | Method for proliferating stem cells with leptin | |
Carotta et al. | Transient Notch signaling induces NK cell potential in Pax5‐deficient pro‐B cells | |
CN102282250A (zh) | 使哺乳动物祖细胞分化为产生胰岛素的胰岛细胞的方法 | |
CN110055219B (zh) | 一种利用非动员外周血制备异质性造血干祖细胞的方法 | |
Giebel et al. | Self-renewal versus differentiation in hematopoietic stem and progenitor cells: a focus on asymmetric cell divisions | |
KR20120006386A (ko) | 1기 태반조직 유래 줄기세포 및 이를 함유하는 세포치료제 | |
Basak et al. | Human embryonic stem cells hemangioblast express HLA-antigens | |
KR20070099054A (ko) | 세포 | |
CN110551688B (zh) | 一种诱导体细胞重编程为造血干/祖细胞且促进造血干/祖细胞体外扩增的组合物及其应用 | |
Lucas et al. | A linkage between dendritic cell and T-cell development in the mouse thymus: the capacity of sequential T-cell precursors to form dendritic cells in culture | |
WO2015152305A1 (ja) | 造血細胞の増殖ペプチドおよびその用途 | |
WO1998021313A1 (fr) | Procede pour la mise en culture de cellules souches hematopoïetiques | |
AU4814997A (en) | Method of producing a thymic microenvironment that supports the development of dendritic cells | |
Hefei et al. | Morphological characteristics and identification of islet‐like cells derived from rat adipose‐derived stem cells cocultured with pancreas adult stem cells | |
Plotkin | Differentiation of Functional Human Mast Cells from Adipose Derived Stem Cells and their Application in Allergo-oncology and the Treatment of Breast Cancer | |
DeLuca et al. | Production of human B cells from CD34+ CD38− T− B− progenitors in organ culture by sequential cytokine stimulation | |
Lu et al. | Isolation and propagation of mouse liver-derived dendritic cells |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
CX01 | Expiry of patent term | ||
CX01 | Expiry of patent term |
Granted publication date: 20051123 |